Thursday, April 10, 2014
Bankole A. Johnson, D.Sc., M.D., M.B., Ch.B., M.Phil., Professor and Chair of the Department of Psychiatry and Behavioral Science at the University of Maryland School of Medicine (SOM) and Dean E. Albert Reece, M.D., Ph.D., M.B.A., are pleased to announce the appointment of leading behavioral neuroscience expert Diana H. Fishbein, Ph.D., as Director of the new SOM Center for Translational Research on Adversity, Neurodevelopment and Substance Abuse (C-TRANS). Dr. Fishbein joins the SOM from RTI (Research Triangle Institute) International in North Carolina, where she served as Program Director and Senior Fellow for the Transdisciplinary Science and Translational Prevention Program.
“Dr. Fishbein is a leading and internationally recognized expert in behavioral neuroscience as well as a contributor to dialogue on mental health and drug abuse at the federal policy level,” said Dean Reece, Vice President for Medical Affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor. “We are delighted and honored to have Dr. Fishbein join our faculty at the University of Maryland School of Medicine in her new role as director of our new Center, particularly as we increase our focus on brain science and translational research across departments.”
As C-TRANS Director, Dr. Fishbein leads a group of clinician and basic scientists who share a common interest in translational neuroscience research to improve the lives of those who suffer from sleep disorders, drug abuse, and more. She is founder and chair for the Coalition for Science-Based Solutions to Promote Child and Adolescent Wellbeing, an informal national association to promote transfer of scientific knowledge to communities and policy-makers. She also is a national policy leader in mental health, having recently addressed a congressional hearing on mental health and drug abuse on how prevention strategies need to be used to avert child and adolescent mental, emotional, and behavioral problems and thus alleviate social and economic burdens for treatment and care.
Dr. Fishbein joins the SOM faculty as Professor in the Department of Psychiatry. She is also an adjunct faculty member at the Johns Hopkins University School of Public Health, and is a guest researcher at the National Institute on Drug Abuse (NIDA). She is involved in various stages of five existing NIH grants related to sleep disorders and drug abuse totaling more than $12 million.
“I have been working my entire career toward the goal of developing a leading university center focusing on adversity and neurodevelopment,” said Dr. Fishbein. “I’m so grateful for this opportunity at the University of Maryland School of Medicine and look forward to forging new ground with the faculty and making a meaningful difference in the study of mental health and substance abuse.”
Dr. Fishbein publishes regularly in her field and is primary author of two textbooks, The Dynamics of Drug Abuse and Biobehavioral Perspectives in Criminology. She is also the editor of two volumes of The Science, Treatment and Prevention of Antisocial Behavior and editor of Behavioral Inhibitory Processes and Drug Abuse: Implications for Prevention and Treatment. She completed her B.S. in Criminology with Statistics Minor, M.S. in Criminology and a Ph.D. in Criminology and Psychobiology all at Florida State University.
“The SOM seeks to provide excellence in biomedical education, basic and clinical research, quality patient care and service to improve the health of the citizens of Maryland and beyond,” added Dean Reece. “Dr. Fishbein’s important work and research exemplifies that mission. Under her leadership, I anticipate C-TRANS advancing our already robust translational research program in the vital areas of mental health and substance abuse.”